TABLE 3

Clinical trials using MSCs for the purpose of immunomodulation

Condition/therapySite/sponsorStatus
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and GVHDHematological malignancies BM-derived donor MSCUniversity Hospital of Liege, BelgiumRecruiting
Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)Multiple sclerosis BM-derived autologous MCSUniversity of Cambridge, U.K.Not yet recruiting
Prochymal Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-Severe Crohn's DiseaseCrohn's disease BM-derived allogeneic MSC (Prochymal)OsirisTherapeutics, U.S.Active, not recruiting
Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute GVHD or Poor Graft FunctionGVHD BM-derived allogeneic MCSUniversity Hospital of Liege, Katholieke Universiteit Leuven, BelgiumRecruiting
Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of GVHDGVHD BM-derived donor MCSChristian Medical College, IndiaRecruiting
Treatment of Refractory GVHD by the Infusion of Expanded In-Vitro Allogeneic Mesenchymal Stem CellGVHD BM-derived allogeneic MSCUniversity of Salamanca, SpainRecruiting
Extended Evaluation of PROCHYMAL Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's DiseaseCrohn's disease BM-derived allogeneic MSC (Prochymal)Osiris Therapeutics, U.S.Recruiting
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHDGVHD BM-derived allogeneic MSC (Prochymal)Osiris Therapeutics, U.S.Recruiting
Follow-up Study to Evaluate the Safety of Prochymal for the Treatment of GVHD PatientsGVHD BM-derived allogeneic MSCM.D. Anderson Cancer Center, TX Osiris Therapeutics, U.S.Active, not recruiting
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Gastrointestinal Graft Versus Host DiseaseGVHD BM-derived allogeneic MSC (Prochymal)Osiris Therapeutics, U.S.Completed
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic GVHD After Undergoing a Donor Stem Cell TransplantGVHD BM-derived donor MSCCase Comprehensive Cancer Center, U.S. National Cancer Institute (NCI)Recruiting
Evaluation of PROCHYMAL Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's DiseaseCrohn's disease BM-derived allogeneic MSC (Prochymal™)Osiris Therapeutics, U.S.Recruiting
Prochymal Infusion for the Treatment of Steroid-Refractory Acute GVHDGVHD BM-derived allogeneic MSC (Prochymal)M.D. Anderson Cancer Center, TX Osiris Therapeutics, U.S.Recruiting
Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD PatientsGVHD BM-derived allogeneic MSC (Prochymal)Osiris Therapeutics, U.S.Completed
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematological MalignanciesHematological malignancies BM-derived autologous MSCJohnson Comprehensive Cancer Center, USA National Cancer Institute (NCI)Active, not recruiting
Efficacy and Safety of Prochymal Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHDGVHD BM-derived allogeneic MSC (Prochymal)Osiris Therapeutics, U.S.Recruiting
  • BM, bone marrow; Prochymal, allogenic human MSC produced by Osiris Therapeutics.